Aptose Biosciences Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 13, 2026, the registrant had 2,552,429 common shares outstanding. TABLE OF CONTENTS PART I—FINANCIAL INFORMATION4Item 1 – Financial Statements4Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3 – Qualitative and Quantitative Disclosures about Market Risk34Item 4 – Controls and Procedures34 PART II—OTHER INFORMATIONItem 1 – Legal ProceedingsItem 1A – Risk FactorsItem 6 – ExhibitsSignatures CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements within the meaning of the United States Private Securities Litigation ReformAct of 1995 and “forward-looking information” within the meaning of applicable Canadian securities law, which we collectively referto as “forward-looking statements”. Such forward-looking statements reflect our current beliefs and are based on information currentlyavailable to us. In some cases, forward-looking statements can be identified by terminology such as “may,” “would,” “could,” “will,”“should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “hope,” “foresee” or thenegative of these terms or other similar expressions concerning matters that are not historical facts. Many factors could cause our actual results, performance or achievements to be materially different from any future results,performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: •the Arrangement and its expected terms, benefits, timing and closing, including satisfaction of customary closingconditions, and the anticipated timing thereof;•our ability to continue as a going concern;•our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and onacceptable terms;•if a financing is completed, it may not be a large enough financing to fully fund the company's operations;•our suppliers or clinical sites may choose to implement work stoppage on key programs, change the terms of contracts orterminate contracts for key programs;•our conversations with partners to renegotiate existing product license agreements may not be successful;•our lack of product revenues and net losses and a history of operating losses;•our ability to meet the continued listing requirements of the TSX and the listing requirements to relist on The Nasdaq StockMarket (the "Nasdaq");•our early stage of development, particularly the inherent risks and uncertainties associated with (i) developing new drugcandidates generally, (ii) demonstrating the safety and efficacy of these drug candidates in clinical studies in humans, and(iii) obtaining regulatory approval to commercialize these drug candidates;•further equity financing, which may substantially dilute the interests of our existing shareholders;•clinical studies and regulatory approvals of our drug candidates are subject to delays, and may not be completed or grantedon expected timetables, if at all, and such delays may increase our